Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BIVINASDAQ:CRVONASDAQ:PYXSNASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBIVIBioVie$1.08-0.9%$0.96$0.62▼$7.50$20.05M0.771.84 million shs194,103 shsCRVOCervoMed$7.62+1.1%$8.96$1.80▼$22.57$66.32M-0.731.34 million shs93,099 shsPYXSPyxis Oncology$1.35+8.9%$1.09$0.83▼$5.39$83.63M1.18743,698 shs620,781 shsTELOTelomir Pharmaceuticals$2.15+7.0%$2.47$1.87▼$8.40$63.99M-0.38147,653 shs181,969 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBIVIBioVie0.00%+6.40%-12.20%-9.24%+120.41%CRVOCervoMed0.00%+7.17%-14.38%+244.80%-61.28%PYXSPyxis Oncology0.00%+11.57%+24.42%+16.38%-62.71%TELOTelomir Pharmaceuticals0.00%+10.26%-13.90%-50.57%-57.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBIVIBioVie1.3999 of 5 stars3.82.00.00.00.00.00.6CRVOCervoMed2.8446 of 5 stars4.43.00.00.00.61.70.6PYXSPyxis Oncology1.8907 of 5 stars3.41.00.00.03.20.80.6TELOTelomir Pharmaceuticals2.4539 of 5 stars3.81.00.00.03.00.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBIVIBioVie 3.50Strong Buy$3.00177.78% UpsideCRVOCervoMed 2.89Moderate Buy$27.63262.53% UpsidePYXSPyxis Oncology 2.80Moderate Buy$9.00566.67% UpsideTELOTelomir Pharmaceuticals 3.50Strong Buy$15.00597.67% UpsideCurrent Analyst Ratings BreakdownLatest BIVI, CRVO, PYXS, and TELO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.005/13/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.005/12/2025CRVOCervoMedChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$14.00 ➝ $15.003/26/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/19/2025PYXSPyxis OncologyRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.003/19/2025PYXSPyxis OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.003/18/2025BIVIBioVieBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/18/2025CRVOCervoMedRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $20.003/18/2025CRVOCervoMedCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$12.00 ➝ $21.003/17/2025CRVOCervoMedD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/13/2025CRVOCervoMedJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$15.00(Data available from 6/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBIVIBioVieN/AN/AN/AN/A$2.54 per shareN/ACRVOCervoMed$7.14M9.29N/AN/A$1.30 per share5.86PYXSPyxis Oncology$16.15M5.18N/AN/A$2.81 per share0.48TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.02 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBIVIBioVie-$32.12M-$7.91N/A∞N/AN/A-134.07%-93.44%8/21/2025 (Estimated)CRVOCervoMed-$2.17M-$2.18N/AN/AN/A-118.68%-44.11%-39.81%8/8/2025 (Estimated)PYXSPyxis Oncology-$73.79M-$1.59N/AN/AN/AN/A-36.22%-28.76%8/13/2025 (Estimated)TELOTelomir Pharmaceuticals-$16.53M-$0.42N/AN/AN/AN/A-1,170.58%-832.67%8/12/2025 (Estimated)Latest BIVI, CRVO, PYXS, and TELO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025PYXSPyxis Oncology-$0.29-$0.35-$0.06-$0.35N/AN/A5/12/2025Q3 2025BIVIBioVie-$0.32-$0.15+$0.17-$0.15N/AN/A5/12/2025Q1 2025CRVOCervoMed-$0.60-$0.56+$0.04-$0.56$1.70 million$1.92 million5/12/2025Q1 2025TELOTelomir Pharmaceuticals-$0.10-$0.07+$0.03-$0.07N/AN/A3/18/2025Q4 2024PYXSPyxis Oncology-$0.33-$0.32+$0.01-$0.60N/A$16.15 million3/17/2025Q4 2024CRVOCervoMed-$0.67-$0.80-$0.13-$0.80$1.51 million$2.16 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBIVIBioVieN/AN/AN/AN/AN/ACRVOCervoMedN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBIVIBioVieN/A16.9416.94CRVOCervoMedN/A15.0415.04PYXSPyxis OncologyN/A7.337.33TELOTelomir PharmaceuticalsN/A1.941.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBIVIBioVie4.59%CRVOCervoMed25.15%PYXSPyxis Oncology39.09%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipBIVIBioVie4.00%CRVOCervoMed35.40%PYXSPyxis Oncology10.60%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBIVIBioVie1018.56 million17.71 millionNo DataCRVOCervoMed48.70 million3.93 millionNot OptionablePYXSPyxis Oncology6061.95 million53.64 millionOptionableTELOTelomir Pharmaceuticals129.76 millionN/AN/ABIVI, CRVO, PYXS, and TELO HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...June 7 at 10:51 AM | usatoday.comTELO Data Indicates Aging Reversal PotentialJune 6 at 1:09 AM | finance.yahoo.comTelomir Pharmaceuticals Announces Telomir-1 Resets the Body's Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated Aging Animal Model of Werner SyndromeJune 5 at 8:30 AM | accessnewswire.comTelomir announces positive preclinical data for its novel oral AMD therapeuticJune 3, 2025 | ophthalmologytimes.comTelomir Pharmaceuticals Joins BIO Convention for PartnershipsJune 2, 2025 | tipranks.comTelomir Pharmaceuticals to Participate in BIO 2025 in Boston as Company Prepares for IND Submission and Advances Breakthrough Longevity PlatformJune 2, 2025 | accessnewswire.comTelomir Pharmaceuticals, Inc: Telomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration Animal Model Using FDA ...May 29, 2025 | finanznachrichten.deTELO Produces Results with Exciting AMD ImplicationsMay 29, 2025 | msn.comTelomir Pharmaceuticals Confirms Telomir-1 Restores Vision and Retinal Structure in Age-Related Macular Degeneration (AMD) Animal Model Using FDA-Recognized Surrogate EndpointsMay 29, 2025 | accessnewswire.comTelomir Pharmaceuticals CFO Michelle Yanez Leaves Company; Resignation Was a Mutual SeparationMay 21, 2025 | marketwatch.comTelomir Pharmaceuticals Appoints New Chief Financial OfficerMay 21, 2025 | tipranks.comTelomir Pharmaceuticals Secures $3 Million at a Premium in Straight Equity Sale Involving No Warrants to Advance Rare Disease INDMay 21, 2025 | accessnewswire.comTelomir PharmaceuticalsMay 19, 2025 | thepharmaletter.comTelomir Pharma touts breakthrough in drug-resistant infectionsMay 16, 2025 | thepharmaletter.comTelomir unveils new drug candidate against resistant bacteriaMay 16, 2025 | investing.comTELO Announces Exciting DiscoveryMay 15, 2025 | msn.comTelomir Pharmaceuticals Adds Telomir-Ag2 as a Novel Drug Candidate to Pipeline Following Breakthrough Efficacy Against MARSA and Drug-Resistant Infections, Targeting a $30B+ Antimicrobial Market OpportunityMay 15, 2025 | accessnewswire.comTELO Announces Promising Aging Reversal Test ResultsMay 8, 2025 | msn.comTelomir Pharmaceuticals Unveils Promising Preclinical Data on Telomir-1May 7, 2025 | tipranks.comTelomir Pharmaceuticals Demonstrates Telomir-1 Reverses Key Drivers of Cellular Decline in Human Cell Lines Supporting Therapeutic Potential in Autism and Spasmodic DysphoniaMay 7, 2025 | accessnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBIVI, CRVO, PYXS, and TELO Company DescriptionsBioVie NASDAQ:BIVI$1.08 -0.01 (-0.92%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.11 +0.03 (+2.69%) As of 06/6/2025 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.CervoMed NASDAQ:CRVO$7.62 +0.08 (+1.06%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$7.56 -0.05 (-0.72%) As of 06/6/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.Pyxis Oncology NASDAQ:PYXS$1.35 +0.11 (+8.87%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$1.30 -0.05 (-3.33%) As of 06/6/2025 06:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Telomir Pharmaceuticals NASDAQ:TELO$2.15 +0.14 (+6.97%) Closing price 06/6/2025 04:00 PM EasternExtended Trading$2.12 -0.02 (-1.16%) As of 06/6/2025 07:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/02 - 06/06 This Banking Giant Just Got a $90 Price Target Upgrade Broadcom Slides on Solid Earnings, AI Outlook Still Strong The Market’s Silent Warning: What Bonds and Gold Reveal Intel's Dual Gamble: AI Innovation Now, Foundry Fortunes Later? MongoDB Affirms Outlook and Accelerates Stock Price Reversal Five Below Pops on Strong Earnings, But Rally May Stall Are NVIDIA's Ethernet Wins Signs of Hope or Horror for Arista? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
